As evidenced by the study by Scheid et al., Tn-MUC1 was established as an efficacious immunotherapeutic target in non-metastatic castration-resistant prostate cancer patients, with the Tn-MUC1 DC vaccine inducing T-cell responses in Phase I/II clinical trials and significantly extending PSADT, indicative of decelerated cancer progression and highlighting the therapeutic promise of Tn-MUC1 in immunotherapy (173). Here, MUC1 is linked to prostate cancer.